Immediate Impact
52 standout
Citing Papers
Regulation of the cGAS-STING Pathway
2025 Standout
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
2025 Standout
Works of Deqiang Wang being referenced
A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer
2021
Polymorphisms in mismatch repair genes are associated with risk and microsatellite instability of gastric cancer, and interact with life exposures
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Deqiang Wang | 305 | 485 | 300 | 358 | 91 | 1.0k | |
| Shanming Ruan | 420 | 602 | 257 | 422 | 72 | 1.3k | |
| Kun Zhu | 277 | 535 | 207 | 301 | 83 | 1.2k | |
| Peng Chen | 436 | 436 | 379 | 253 | 110 | 1.1k | |
| Tonghui Ma | 233 | 640 | 265 | 272 | 124 | 1.3k | |
| Sachin Kumar | 273 | 570 | 237 | 509 | 61 | 1.2k | |
| Wei Wang | 301 | 466 | 162 | 244 | 83 | 1.0k | |
| Feng Xu | 254 | 597 | 267 | 337 | 58 | 1.3k | |
| Kenji Kamiya | 350 | 772 | 186 | 258 | 88 | 1.4k | |
| Feng Li | 229 | 457 | 192 | 298 | 73 | 1.1k | |
| Chaojun Wang | 292 | 529 | 247 | 209 | 67 | 1.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...